Amplify Transformational Data Sharing ETF vs Zimmer Biomet Holdings Inc — how do they compare? Amplify Transformational Data Sharing ETF trades at $59.55, while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Amplify Transformational Data Sharing ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Amplify Transformational Data Sharing ETF nearer its low. Which is the better fit depends on your goals.
| BLOK | ZBH | |
|---|---|---|
52-Week High | $74.10 | $107.71 |
52-Week Low | $47.36 | $79.58 |
Market Cap | — | $18.55B |
Sector | — | Health |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $60.12, up 1.76% with bearish technical signals from moving averages. The ETF shows mixed sentiment with institutional position adjustments and positive coverage on AI infrastructure exposure. Key support sits at $58-59 while resistance levels begin at $61.
Outlook remains cautious given bearish technical indicators and institutional selling pressure. The fund's diversified blockchain economy exposure offers growth potential but faces volatility risks from sector concentration and regulatory uncertainty.
Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.
The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.
Trailing returns across standard periods
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →